Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
BTX's Cash to Debt is ranked higher than
95% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. BTX: No Debt )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.26
BTX's Equity to Asset is ranked higher than
52% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BTX: 0.26 )
BTX' s 10-Year Equity to Asset Range
Min: -17.41   Max: 0.93
Current: 0.26

-17.41
0.93
Interest Coverage No Debt
BTX's Interest Coverage is ranked higher than
89% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BTX: No Debt )
BTX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -4.00
M-Score: -3.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1262.63
BTX's Operating margin (%) is ranked higher than
53% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. BTX: -1262.63 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46   Max: -116.83
Current: -1262.63

-9788.46
-116.83
Net-margin (%) -989.69
BTX's Net-margin (%) is ranked higher than
53% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. BTX: -989.69 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15   Max: -137.48
Current: -989.69

-9471.15
-137.48
ROE (%) -296.49
BTX's ROE (%) is ranked lower than
52% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. BTX: -296.49 )
BTX' s 10-Year ROE (%) Range
Min: -894.2   Max: -29.3
Current: -296.49

-894.2
-29.3
ROA (%) -76.01
BTX's ROA (%) is ranked higher than
54% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. BTX: -76.01 )
BTX' s 10-Year ROA (%) Range
Min: -821.71   Max: -21
Current: -76.01

-821.71
-21
ROC (Joel Greenblatt) (%) -1867.41
BTX's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. BTX: -1867.41 )
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33633.33   Max: -400
Current: -1867.41

-33633.33
-400
Revenue Growth (%) -3.90
BTX's Revenue Growth (%) is ranked higher than
71% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. BTX: -3.90 )
BTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 128.9
Current: -3.9

0
128.9
EBITDA Growth (%) 63.40
BTX's EBITDA Growth (%) is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. BTX: 63.40 )
BTX' s 10-Year EBITDA Growth (%) Range
Min: -48.9   Max: 63.9
Current: 63.4

-48.9
63.9
EPS Growth (%) 42.50
BTX's EPS Growth (%) is ranked higher than
96% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. BTX: 42.50 )
BTX' s 10-Year EPS Growth (%) Range
Min: -35.6   Max: 67.1
Current: 42.5

-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BTX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.40
BTX's P/B is ranked lower than
65% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BTX: 10.40 )
BTX' s 10-Year P/B Range
Min: 5.65   Max: 83
Current: 10.4

5.65
83
P/S 38.70
BTX's P/S is ranked lower than
71% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. BTX: 38.70 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 124
Current: 38.7

4.83
124
EV-to-EBIT 20.80
BTX's EV-to-EBIT is ranked higher than
54% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. BTX: 20.80 )
BTX' s 10-Year EV-to-EBIT Range
Min: 36   Max: 93.1
Current: 20.8

36
93.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
BTX's Price/Median PS Value is ranked higher than
82% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BTX: 1.00 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 9.73
Current: 1

0.14
9.73
Forward Rate of Return (Yacktman) 42.17
BTX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. BTX: 42.17 )
BTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.5   Max: 21.5
Current: 42.17

4.5
21.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany
BioTime, Inc. was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. The Company has historically developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. Its focus is in the field of regenerative medicine; specifically human embryonic stem ("hES") cell and induced pluripotent stem ("iPS") cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. The Company plans to develop stem cell products for research and therapeutic use through its subsidiaries. OncoCyte Corporation is developing products and technologies to diagnose and treat cancer. ES Cell International Pte., Ltd. ("ESI"), a Singapore private limited company, develops and sells hES products for research use. BioTime Asia, Limited a Hong Kong company, sells products for research use and may develop therapies to treat cancer, neurological, and orthopedic diseases. OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc., formerly known as Embryome Sciences, Inc. is developing therapies to treat vascular and blood diseases and disorders. Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. markets GeneCards, the human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. Its products for use in stem cell research are being offered to researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. As of March 18, 2013, the company owned or controlled or licensed directly or through its subsidiaries 281 issued or allowed U.S. patents and also owned or controlled over 141 pending U.S. patent applications, including provisional patent applications, to protect its proprietary technologies. The Company also licensed 140 IP patents and applications from WARF. The Company and its subsidiaries face competition in both blood plasma expander business and regenerative medicine and stem cell business.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide